^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | etoposide IV (Topoisomerase II inhibitor) + decitabine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4131 Combination of Decitabine and Etoposide Is Highly Effective in Treating p53-Mutated MDS/AML Via Activating Notch Signaling
Published date:
11/02/2023
Excerpt:
Patients with TP53 mutations showed higher response rate after two cycles of D+E therapy and had prolonged overall survival (Mutation vs WT: 31 months vs 9 months, p=0.012) and event-free survival (Mutation vs WT: 24 months vs 5 months, p = 0.022) compared with p53 wild type patients in D+E group from multivariate survival analyses.
